Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art

Campanati, Anna; Gregoriou, Stamatis; Kontochristopoulos, George; Offidani, Annamaria

doi:10.1159/000371581

Cited by 23 publications

(26 citation statements)

References 35 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, their clinical utility is greatly limited due to tolerability concerns associated with systemic adverse events. 2,11,50,65 As these agents act systemically without targeting a specific body area, they decrease sweating over the entire body. Although compensatory sweating is not observed, this may entail a tendency towards hyperthermia.…”

Section: Systemic Therapymentioning

confidence: 99%

“…50 Incidence of side effects is generally dose-related but more frequent when daily oxybutynin doses exceed 10-15 mg/ day. 50,65 Long-term evidence reveals that anticholinergic therapy does not demonstrate tachyphylaxis (decreased response to repeated drug doses). 50 On average, side effects are often intolerable enough to force up to one-third of patients to withdraw from treatment despite good control of hyperhidrosis.…”

Section: Systemic Therapymentioning

confidence: 99%

“…52 This suggests that a stepwise up-titration to the lowest dose of anticholinergics that achieves both efficacy and tolerability is needed to optimize therapeutic compliance. 11,15,65,66 It has also been suggested that if initial therapy with one oral anticholinergic agent, such as oxybutynin, is either intolerable or ineffective, the use of another, such as glycopyrrolate, will not necessarily fail in the same way and could represent a viable alternative. 63 Of note, recent research into methods of reducing anticholinergic side effects has yielded promising results.…”

Section: Systemic Therapymentioning

confidence: 99%

See 2 more Smart Citations

<p>Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions</p>

Gregoriou

Sidiropoulou

Kontochristopoulos

et al. 2019

CCID

View full text Add to dashboard Cite

Palmar hyperhidrosis is a potentially disabling condition for which management remains a therapeutic challenge. Given the significant impact on quality of life, various treatment options are available, ranging from topical agents and medical devices to systemic therapies and surgical interventions. Nonsurgical approaches, i.e. topical antiperspirants, botulinum toxin injections, iontophoresis, and systemic agents, are all supported by the current literature. Patients with mild-to-moderate disease can often benefit from topical therapies only. As disease severity progresses, systemic oral medication, such as anticholinergic drugs, usually becomes necessary. Last-line surgical approaches (sympathetic denervation) should be reserved for severe refractory cases. Recently, therapeutic strategies have been evolving with several new agents emerging as promising alternatives in clinical trials. In practice, however, each modality comes with its own benefits and risks. An individual therapeutic ladder is generally recommended, taking into account disease severity, benefit-to-risk profile, treatment cost, patient preference, and clinician expertise. This review will provide an update on current and emerging concepts of management for excessive hand sweating to help clinicians optimize therapeutic decision-making.

show abstract

Section: Systemic Therapymentioning

confidence: 99%

Section: Systemic Therapymentioning

confidence: 99%

Section: Systemic Therapymentioning

confidence: 99%

See 1 more Smart Citation

<p>Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions</p>

Gregoriou

Sidiropoulou

Kontochristopoulos

et al. 2019

CCID

View full text Add to dashboard Cite

show abstract

“…The skin around the eyes, nose and mouth should be avoided [22]. A 0.5% cream with glycopyrrolate has found application, among others, in the treatment of secondary hyperhidrosis in diabetic patients [23].…”

Section: Topical Treatmentmentioning

confidence: 99%

“…Należy omijać okolice oczu, nosa i ust [22]. Krem z glikopirolanem 0,5% znalazł zastosowanie między innymi w terapii wtórnej nadpotliwości u pacjentów z cukrzycą [23].…”

Section: Leczenie Miejscoweunclassified

Hyperhidrosis – pathogenesis and treatment methods

Sazanów-Lubelski¹,

Bergler‐Czop²,

Barasińska³

et al. 2018

View full text Add to dashboard Cite

Hyperhidrosis is a condition characterized by excessive sweating which may have a primary or secondary cause. The diagnosis is facilitated by the guidelines of the Canadian Hyperhidrosis Advisory Committee. Prior to initiating treatment, the severity of the condition is determined based on the Hyperhidrosis Disease Severity Scale or objective examinations (Minor test or gravimetric method). The therapeutic options depend on the type of hyperhidrosis and are divided into topical, systemic and procedural modalities. The first-line drugs are topical preparations including aluminium salts, glycopyrrolate 2% and tannic acid solutions. Systemic therapies are based primarily on anti-cholinergic and β-adrenolytic drugs. Procedural therapies include botulinum toxin treatment, iontophoresis, laser therapy as well as techniques based on microwaves and ultrasounds. If these modalities fail, the remaining option is surgery, including sympathectomy or surgical removal of sweat glands. streszczenie Nadpotliwość to nadmierne wydzielanie potu, które może mieć przyczynę pierwotną lub wtórną. Diagnozę ułatwiają wytyczne Canadian Hyperhidrosis Advisory Committee. Przed rozpoczęciem terapii określa się stopień nasilenia dolegliwości wg skali subiektywnej (Hyperhidrosis Disease Severity Scale) lub obiektywnych badań (test Minora, metoda grawimetryczna). Leczenie zależy od typu nadpotliwości i dzieli się na miejscowe, ogólne i zabiegowe. Preparaty miejscowe: sole glinu, 2% glikopirolan i roztwory kwasu taninowego, są lekami pierwszego wyboru. W terapii ogólnej stosuje się głównie leki antycholinergiczne i β-adrenolityczne. Do metod zabiegowych należą: terapia toksyną botulinową, jonoforeza, laseroterapia, zastosowanie mikrofal i ultradźwięków. Jeżeli powyższe metody zawiodą, pozostaje leczenie operacyjne-sympatektomia lub chirurgiczne usunięcie gruczołów potowych.

show abstract

Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics

Wong

Adlam

Potts

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Background Topical anticholinergics have been reported to be effective in managing hyperhidrosis (HH) given the recent approval of glycopyrronium tosylate. Objective This review aimed to examine the effectiveness of emerging topical anticholinergic treatments for HH and their associated adverse effects in comparison to current treatment options. Methods We conducted a search within the PubMed and Embase databases for current and emerging topical anticholinergic treatments for primary HH. Results The topical anticholinergics that have been recently investigated for use in HH include glycopyrrolate, oxybutynin, sofpironium bromide, and umeclidinium. The only agent currently FDA approved is glycopyrrolate. Conclusion Knowledge of topical anticholinergic treatment options is important for patient care when managing HH. This review shows that while available safety data thus far are limited, emerging topical anticholinergics pose minimal known human risks.

show abstract

Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art

Cited by 23 publications

References 35 publications

<p>Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions</p>

<p>Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions</p>

Hyperhidrosis – pathogenesis and treatment methods

Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics

Contact Info

Product

Resources

About